Skip to main content

Advertisement

Log in

SGLT2 inhibitors and euglycemic diabetic ketoacidosis

European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Available upon request.

References

  1. Bamgboye AO, Oni IO, Collier A (2020) Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-020-03051-3

  2. Clark A, Mohammed AS, Raut A, Moore S, Houlden R, Awad S (2020) Prevalence and clinical characteristics of adults presenting with sodium-glucose cotransporter-2 inhibitor-associated diabetic ketoacidosis at a Canadian Academic Tertiary Care Hospital. Can J Diabetes. https://doi.org/10.1016/j.jcjd.2020.08.100

  3. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535

    Article  PubMed  PubMed Central  Google Scholar 

  4. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008–2012. https://doi.org/10.1001/jama.283.15.2008

    Article  CAS  PubMed  Google Scholar 

  5. Lo CK, Mertz D, Loeb M (2014) Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 14:45. https://doi.org/10.1186/1471-2288-14-45

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Funding for publications costs is covered by Hamad Medical Corporation.

Author information

Authors and Affiliations

Authors

Contributions

Fateen Ata: Principal investigator, conceptualization, literature review, data gathering, manuscript writing. Zohaib Yousaf: Literature review, data gathering, statistical analysis, manuscript writing. Adeel Ahmad Khan: Literature review, data gathering, manuscript writing. Almurtada Razok: Literature review, data gathering. Jaweria Akram: Literature review, data gathering. Elrazi Awadelkarim Hamid Ali: Literature review, data gathering. Ahmed Abdalhadi: Literature review, data gathering. Mohammed I Danjuma: Literature review and manuscript writing. Dabia Hamad S H Al Mohanadi: Literature review, manuscript writing and supervision. All authors have reviewed and approved the final version of the manuscript.

Corresponding author

Correspondence to Fateen Ata.

Ethics declarations

Ethics approval and consent to participate

The study was approved by MRC Qatar (MRC-01-20-064). Consent was not required as this was a retrospective data review of medical records.

Consent for publication

Consent was not required as this was a retrospective data review of medical records.

Conflict of interest

The authors declare no competing interests.

Additional information

This work has not been submitted and is not under consideration in any other journal.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yousaf, Z., Ata, F., Khan, A.A. et al. SGLT2 inhibitors and euglycemic diabetic ketoacidosis. Eur J Clin Pharmacol 77, 1431–1433 (2021). https://doi.org/10.1007/s00228-021-03120-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-021-03120-1

Navigation